Development of leading first-generation vaccines against SARS-CoV-2

Pin-Yu Perera; Liyanage P Perera

doi:10.1016/j.micinf.2021.104841

Development of leading first-generation vaccines against SARS-CoV-2

Microbes Infect. 2021 Sep-Oct;23(8):104841. doi: 10.1016/j.micinf.2021.104841. Epub 2021 May 20.

Authors

Pin-Yu Perera¹, Liyanage P Perera²

Affiliations

¹ Pathology and Laboratory Medicine, Veterans Affairs Medical Center, Washington, DC, USA. Electronic address: [email protected].
² Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Abstract

SARS-CoV-2 has infected more than 167 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late phase clinical trials to meet this urgent need.

Keywords: Animal models; Clinical trials; Covid-19; SARS-CoV-2; Vaccines.

Published by Elsevier Masson SAS.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Humans
SARS-CoV-2* / genetics
SARS-CoV-2* / immunology

Substances

COVID-19 Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding